Febuxostat
[CAS# 144060-53-7]

Identification

• Classification: API >> Antipyretic analgesics >> Anti-gout medicine
• Name: Febuxostat
• Synonyms: 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid; 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
• Molecular Formula: C₁₆H₁₆N₂O₃S
• Molecular Weight: 316.37
• CAS Registry Number: 144060-53-7
• EC Number: 682-158-6
• SMILES: CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H413
• Safety Statements: P264-P270-P273-P301+P317-P330-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute toxicity	Acute Tox.	4	H302
Chronic hazardous to the aquatic environment	Aquatic Chronic	4	H413
Skin irritation	Skin Irrit.	2	H315
Specific target organ toxicity - repeated exposure	STOT RE	2	H373
Acute toxicity	Acute Tox.	3	H301
Acute toxicity	Acute Tox.	4	H312
Acute toxicity	Acute Tox.	4	H332
Reproductive toxicity	Lact.	-	H362
Eye irritation	Eye Irrit.	2	H319

Discovery and Applications

Febuxostat was discovered in the early 2000s during efforts to develop new treatments for hyperuricemia and gout, conditions characterized by elevated uric acid levels in the blood. Traditional treatments like allopurinol had limitations due to side effects and efficacy, particularly in patients with renal impairment. Researchers at Teijin Pharma identified febuxostat through a series of structure-activity relationship (SAR) studies focused on inhibiting xanthine oxidase, the enzyme responsible for converting hypoxanthine to uric acid. Febuxostat's non-purine structure and potent inhibitory activity against xanthine oxidase distinguished it from existing treatments, leading to its approval by the FDA in 2009 as a novel urate-lowering therapy.

Febuxostat is primarily used for managing chronic gout, a condition resulting from hyperuricemia where uric acid crystals deposit in joints, causing inflammation and pain. By inhibiting xanthine oxidase, febuxostat reduces uric acid production, helping to lower serum urate levels and prevent gout flares. It serves as an effective alternative to allopurinol, especially for patients who cannot tolerate allopurinol or do not achieve adequate urate reduction. Febuxostat's non-purine structure helps minimize the risk of adverse reactions, making it suitable for a broader patient population. Febuxostat is available in multiple dosages, allowing for flexible dosing to achieve and maintain target urate levels. This flexibility is beneficial in tailoring treatment to individual patient needs and response.

Febuxostat is indicated for long-term management of chronic hyperuricemia in patients with conditions like gout or those undergoing chemotherapy, which can lead to tumor lysis syndrome and increased uric acid levels. Its potent inhibitory effect on xanthine oxidase effectively controls uric acid levels, reducing the risk of urate-related complications. Febuxostat is advantageous for patients with mild to moderate renal impairment, where allopurinol dosage adjustment might be necessary. Its metabolism is less dependent on renal excretion, offering a safer profile in these patients and simplifying dosing considerations.

Emerging research suggests that febuxostat may have cardiovascular benefits beyond urate lowering. By reducing oxidative stress through xanthine oxidase inhibition, febuxostat could help in managing conditions associated with increased oxidative stress, such as hypertension and cardiovascular diseases.There is ongoing investigation into febuxostat's potential role in protecting renal function. Its ability to reduce uric acid levels and oxidative stress may confer benefits in preventing or slowing the progression of kidney disease, particularly in patients with hyperuricemia-related renal damage.

Febuxostat is being studied for potential uses beyond gout and hyperuricemia, including its effects on other metabolic disorders and chronic inflammatory conditions. Researchers are exploring its role in managing conditions like metabolic syndrome and chronic kidney disease, where hyperuricemia may play a contributory role. Clinical studies continue to compare febuxostat with other urate-lowering therapies to refine its role in treatment protocols. These studies aim to optimize its use in various patient populations, including those with comorbid conditions or those who are refractory to other treatments.

While febuxostat is generally well-tolerated, regular monitoring of liver function tests is recommended due to potential hepatic side effects. Patients should also be monitored for cardiovascular events, although febuxostat's safety profile is comparable to other urate-lowering therapies. Effective use of febuxostat involves educating patients about adherence to therapy and lifestyle modifications, such as dietary changes and adequate hydration, to support urate control and prevent gout flares.

References

2018. Xanthine oxidase inhibitors by macrophages. American Journal of Hypertension, 32(1).
DOI: 10.1093/jh/hpy157

2018. Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts. Journal of Pharmacological Sciences, 131(3).
DOI: 10.1016/jphs.2016.03

2015. Febuxostat for the treatment of gout. Expert Opinion on Pharmacotherapy, 16(2).
DOI: 10.1517/14656566.2015